David Kahan, DO
Family Medicine · Tucson, AZNPI 1598741167
Payments from drug & device makers
Across 344 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AbbVie$785
- AstraZeneca$622
- Pfizer$485
- GSK$407
- Lilly USA, LLC$276
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,984100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 62 | $1,113 |
| AbbVie(2 entities) | 41 | $785 |
| AstraZeneca | 28 | $622 |
| Pfizer | 31 | $485 |
| GSK | 24 | $407 |
| Lilly USA, LLC | 16 | $276 |
| Boehringer Ingelheim | 15 | $259 |
| Novo Nordisk | 19 | $251 |
| Abbott | 8 | $162 |
| Exact Sciences | 9 | $156 |
| Merck | 9 | $144 |
| Amarin Pharma, Inc. | 9 | $125 |
| Johnson & Johnson | 9 | $120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $107 |
| Novartis | 6 | $99 |
| Astellas Pharma US Inc | 4 | $80 |
| Viatris Specialty LLC | 4 | $79 |
| Sanofi Pasteur Inc. | 4 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $70 |
| Phathom Pharmaceuticals, Inc. | 3 | $67 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Nestle Healthcare Nutrition Inc. | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Evoke Pharma, Inc. | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Aimmune Therapeutics, Inc. | 2 | $32 |
| Almatica Pharma LLC | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Insulet Corporation | 1 | $22 |
| Boston Scientific | 1 | $19 |
| Radius Health, Inc. | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Smith+Nephew | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Therapeuticsmd, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$123
How this compares
$5,984 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 80 | $93,642 |
| XareltoRivaroxaban | 42 | $43,345 |
| JardianceEmpagliflozin | 29 | $35,004 |
| OzempicSemaglutide | 24 | $30,148 |
| JanuviaSitagliptin Phosphate | 24 | $29,920 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $29,299 |
| RybelsusSemaglutide | 11 | $26,018 |
| ProliaDenosumab | 11 | $19,416 |
| MyrbetriqMirabegron | 12 | $14,288 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $11,331 |
| TrulicityDulaglutide | 11 | $11,114 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $7,966 |
| FarxigaDapagliflozin Propanediol | 11 | $6,518 |
| Atorvastatin Calcium | 580 | $4,835 |
| Levothyroxine Sodium | 459 | $3,899 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $485 | $96,84191 claims |
| Novo NordiskOzempic, Rybelsus | $251 | $56,16635 claims |
| Johnson & JohnsonXarelto | $120 | $43,34542 claims |
| Boehringer IngelheimJardiance | $259 | $35,00429 claims |
| MerckJanuvia | $144 | $29,92024 claims |
| GSKTrelegy Ellipta | $407 | $29,29934 claims |
| AmgenProlia | $1,113 | $19,41611 claims |
| Astellas Pharma US IncMyrbetriq | $80 | $14,28812 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $42 | $11,33112 claims |
| Lilly USA, LLCTrulicity | $276 | $11,11411 claims |
| AstraZenecaFarxiga, Symbicort | $622 | $9,21323 claims |
| AbbVieSynthroid | $785 | $2,36329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Tucson
- Dena PetersenTucson$14.7M
- John McGettiganTucson$8.3M
- Kevin PoundsTucson$1.9M
- Thili KulatilakeTucson$1.8M
- Judith BrownTucson$399K
- Hannah LeslieTucson$228K
- Charles MichieliTucson$111K
- Danielle ArmasScottsdale$73M
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.